US FDA cleared IND application allowing for the start of Ph 1 trial of SP-3164 in patients with R/R NHL
“US Food and Drug Administration has cleared its investigational new drug (IND) application allowing for the start of a Phase I trial of SP-3164 in patients with relapsed or refractory non-Hodgkin lymphoma. In the trial, expected to begin in the second half of this year, Salarius will also evaluate a gene signature for selecting patients who may respond well to the second-generation targeted protein degrader SP-3164. The dose-escalation portion of the study will involve patients with non-Hodgkin lymphoma, and in a second portion of the study, researchers will assess the activity of the drug in patients with diffuse large B-cell lymphoma, Salarius CEO David Arthur said in a statement.”
Share:
More News
Lamine Mbow, Global Head of Discovery Research, Boehringer Ingelheim, said: “We are building a broad pipeline of ADCs addressing novel tumor target space to develop next-generation cancer treatments. By combining our deep expertise in cancer treatment development with Synaffix’s clinical-stage platform technology, we aim to accelerate the delivery of first-in-class
“The initial therapy of high-risk, non-muscle invasive bladder cancer with BCG has not advanced in decades. Today’s pivotal Phase 3 CREST results are potentially practice-changing, representing the first advance in therapy for BCG-naïve, high-risk, non-muscle invasive cancer in over 30 years,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “These
“Receiving FDA IND clearance is an important milestone in the advancement of TYRA-300 and for patients with NMIBC who urgently need better tolerated therapeutic options,” commented Doug Warner, Chief Medical Officer of TYRA. “We look forward to leveraging Erik’s impressive background to guide our development plans in NMIBC. We expect
“As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations,” said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. “We look forward to partnering with Simcere Zaiming, to advance
